[go: up one dir, main page]

Follow
Jack Henningfield
Jack Henningfield
Jack Henningfield, Ph.D. Vice President, Research, Health Policy, and Abuse Liability; Professor, Adjunct, Behavioral Biology, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine
Verified email at pinneyassociates.com - Homepage
Title
Cited by
Cited by
Year
Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana
MA Huestis, JE Henningfield, EJ Cone
Journal of analytical Toxicology 16 (5), 276-282, 1992
7741992
Establishing a nicotine threshold for addiction--the implications for tobacco regulation
NL Benowitz, JE Henningfield
New England Journal of Medicine 331 (2), 123-125, 1994
6581994
Nicotine medications for smoking cessation
JE Henningfield
New England Journal of Medicine 333 (18), 1196-1203, 1995
6221995
Nicotine delivery kinetics and abuse liability.
JE Henningfield, RM Keenan
Journal of consulting and clinical psychology 61 (5), 743, 1993
5831993
The development of a cocaine craving questionnaire
ST Tiffany, E Singleton, CA Haertzen, JE Henningfield
Drug and alcohol dependence 34 (1), 19-28, 1993
5241993
Nicotine and smoking: a review of effects on human performance.
SJ Heishma, RC Taylor, JE Henningfield
Experimental and Clinical Psychopharmacology 2 (4), 345, 1994
4931994
Higher levels of nicotine in arterial than in venous blood after cigarette smoking
JE Henningfield, JM Stapleton, NL Benowitz, RF Grayson, ED London
Drug and alcohol dependence 33 (1), 23-29, 1993
4931993
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
MW Johnson, RR Griffiths, PS Hendricks, JE Henningfield
Neuropharmacology 142, 143-166, 2018
4592018
Epidemiology of tobacco use and dependence.
GA Giovino, JE Henningfield, SL Tomar, LG Escobedo, J Slade
Epidemiologic reviews 17 (1), 48-65, 1995
4471995
Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine.
JE Henningfield, K Miyasato, DR Jasinski
The Journal of pharmacology and experimental therapeutics 234 (1), 1-12, 1985
3981985
Pharmacotherapy for Nicotine Dependence 1
JE Henningfield, RV Fant, AR Buchhalter, ML Stitzer
CA: a cancer journal for clinicians 55 (5), 281-299, 2005
3752005
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.
RJ Lamb, KL Preston, CW Schindler, RA Meisch, F Davis, JL Katz, ...
The Journal of pharmacology and experimental therapeutics 259 (3), 1165-1173, 1991
3641991
Involvement of tobacco in alcoholism and illicit drug use
JE Henningfield, R Clayton, W Pollin
British journal of addiction 85 (2), 279-292, 1990
3361990
Health risks associated with cigar smoking
F Baker, SR Ainsworth, JT Dye, C Crammer, MJ Thun, D Hoffmann, ...
Jama 284 (6), 735-740, 2000
3292000
Psychedelics: Where we are now, why we got here, what we must do
SJ Belouin, JE Henningfield
Neuropharmacology 142, 7-19, 2018
3052018
Nicotine as a reinforcer in human subjects and laboratory animals
JE Henningfield, SR Goldberg
Pharmacology Biochemistry and Behavior 19 (6), 989-992, 1983
2791983
The reemergence of smokeless tobacco
GN Connolly, DM Winn, SS Hecht, JE Henningfield, B Walker Jr, ...
New England Journal of Medicine 314 (16), 1020-1027, 1986
2581986
The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US
M Zeller, D Hatsukami
Tobacco control 18 (4), 324-332, 2009
2562009
Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9 …
MA Huestis, JE Henningfield, EJ Cone
Journal of analytical toxicology 16 (5), 283-290, 1992
2471992
Reducing the nicotine content to make cigarettes less addictive
NL Benowitz, JE Henningfield
Tobacco control 22 (suppl 1), i14-i17, 2013
2442013
The system can't perform the operation now. Try again later.
Articles 1–20